Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $6.3 million.

  • Amphastar Pharmaceuticals' Share-based Compensation rose 1252.68% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.7 million, marking a year-over-year increase of 1432.49%. This contributed to the annual value of $24.4 million for FY2024, which is 2038.34% up from last year.
  • Amphastar Pharmaceuticals' Share-based Compensation amounted to $6.3 million in Q3 2025, which was up 1252.68% from $6.4 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Share-based Compensation ranged from a high of $8.4 million in Q1 2025 and a low of $3.8 million during Q4 2021
  • For the 5-year period, Amphastar Pharmaceuticals' Share-based Compensation averaged around $5.4 million, with its median value being $5.0 million (2022).
  • Its Share-based Compensation has fluctuated over the past 5 years, first tumbled by 3039.12% in 2022, then surged by 2185.2% in 2024.
  • Amphastar Pharmaceuticals' Share-based Compensation (Quarter) stood at $3.8 million in 2021, then increased by 11.79% to $4.3 million in 2022, then increased by 7.39% to $4.6 million in 2023, then increased by 21.85% to $5.6 million in 2024, then grew by 11.81% to $6.3 million in 2025.
  • Its Share-based Compensation stands at $6.3 million for Q3 2025, versus $6.4 million for Q2 2025 and $8.4 million for Q1 2025.